To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

Inclusion Criteria

• •1. Both gender, 19 years ≤ age
• •2. At least two years history of allergic rhinitis prior to participate in clinical trial
• •3. Patients with positive reaction for perennial allergen in tests(prick test or Intradermal test or MAST(Multiple Allergen Simultaneous Test) or Immuno CAP test) within 12 months
• •4. In visit 2, patients with over mean 5 points of the total reflective TNSS score per day (during the run-in period) (highest value 12 points)
• •5. Patients who can ability to record subject diary
• •6. Patients who agreed to maintain the same environment throughout the entire clinical trial period.
• •7. Written consent voluntarily to participate in this clinical trial after understanding and detailed explanation about this clinical trial